{"id":7150,"date":"2025-04-28T11:08:54","date_gmt":"2025-04-28T09:08:54","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=7150"},"modified":"2025-07-29T17:42:53","modified_gmt":"2025-07-29T15:42:53","slug":"comparative-efficacy-of-bruton-tyrosine-kinase-inhibitors-in-high-risk-relapsed-refractory-cll-a-network-meta-analysis","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/comparative-efficacy-of-bruton-tyrosine-kinase-inhibitors-in-high-risk-relapsed-refractory-cll-a-network-meta-analysis\/","title":{"rendered":"Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed\/refractory CLL: a network meta-analysis"},"content":{"rendered":"","protected":false},"template":"","post-tag":[559,613,612,629,673,628,594,656,542],"class_list":["post-7150","publication","type-publication","status-publish","hentry","post-tag-alpine","post-tag-brutons-tyrosine-kinase","post-tag-brutons-tyrosine-kinase-inhibitor","post-tag-btk","post-tag-btk-inhibitor","post-tag-btki","post-tag-chronic-lymphocytic-leukemia","post-tag-cll","post-tag-zanubrutinib","disease_state-chronic-lymphocytic-leukemia","molecule-zanubrutinib"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/7150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7150"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}